Exodus Point Capital Management, LP Allovir, Inc. Transaction History

Exodus Point Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$2.15 - $3.64 $191,876 - $324,851	89,245 Added 344.96%	115,116 $247,000
Q2 2023 Aug 10, 2023	BUY	$3.17 - $5.82 $82,011 - $150,569	25,871 New	25,871 $88,000
Q4 2021 Feb 11, 2022	SELL	$12.94 - $25.99 $205,370 - $412,487	-15,871 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$16.97 - $25.06 $31,750 - $46,887	1,871 Added 13.36%	15,871 $398,000
Q2 2021 Aug 16, 2021	BUY	$19.44 - $25.06 $272,160 - $350,840	14,000 New	14,000 $276,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.